Main responsibilities of Laia Crespo will include the identification and assessment of investment and disinvestment opportunities from the scientific and business perspectives
Barcelona – September 1, 2009 – Endosense, a medical technology company focused on improving efficacy, safety and reproducibility of catheter ablation for the treatment of cardiac arrhythmias, has announced that it has received USD 36 million in Series B financing.
The fund will be invested in 10 to 12 biotechnology companies in the field of human health.
Main responsibilities of Martín-Ruiz will be to analyze and evaluate the feasibility of the target companies of the fund from a scientific and business point of view.
Her appointment comes along with the new stage of the venture capital firm specialized in biotech, which is preparing the first closing of Ysios BioFund I.
Ysios has created this position to manage the increased activity expected as the initial capital subscription of its first fund, Ysios BioFund I, draws to a close
The company anticipates a first closing of around EUR 60 million in brief.
Barcelona, September 20, 2007. ‐ Cellerix, a biopharmaceutical company leader in the clinical development and production of innovative medicines based on adult stem cells, has closed an oversubscribed Series B financing round for €27.2M.
The round was led by two of the most experienced life science investors in Europe, LSP (Netherlands) and Ventech (France).
Subscribe to our weekly newsletter for the latest updates on life sciences investments.